Clinical trials: Advanced Malignant Tumors
Advanced Solid Tumors
A Study of SIGX1094R in Patients With Advanced Solid Tumors
This is a phase I clinical, first-in-human study of SIGX1094R monotherapy. The goal of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), anti-tumor activity and food effect of…
- Trial name
- NCT06739291
- Testing
- SIGX1094R
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Signet Therapeutics
Solid Tumors
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or…
- Trial name
- NCT02598960
- Testing
- BMS-986156, Nivolumab
- Where
- 27 sites in United States, Australia and 8 more
- Volunteers
- 295 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
- Trial name
- NCT02057380
- Testing
- linsitinib, erlotinib, paclitaxel
- Where
- 12 sites in United States, Brazil and 5 more
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.
- Trial name
- NCT02407990
- Testing
- BGB-A317
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 451 people
- Sponsor
- BeiGene
Malignant Solid Tumour, Liver Metastases
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
- Trial name
- NCT00969410
- Testing
- AV-299
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Locally Advanced, Metastatic Solid Tumors
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
The purpose of this study is to compare the safety and tolerability of several dose levels of MK-2206 in combination with chemotherapy and targeted therapy agents in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT00848718
- Testing
- MK-2206, docetaxel, erlotinib
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Melanoma
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma.
- Trial name
- NCT01271803
- Testing
- Cobimetinib, vemurafenib
- Where
- 10 sites in United States, Australia
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
Study of D3L-002 in Subjects With Advanced Solid Tumors
This is a first-in-human, multicenter, open-label, single-arm, dose-escalation Phase 1 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of D3L-002…
- Trial name
- NCT07667842
- Testing
- D3L-002
- Where
- 6 sites in Australia, South Korea
- Volunteers
- 24 people
- Sponsor
- D3 Bio (Wuxi) Co., Ltd
Advanced Solid Tumors Cancer
A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
An open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399 in participants with advanced solid tumors.
- Trial name
- NCT03311477
- Testing
- ABBV-399
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- AbbVie
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Advanced Malignancies
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.
- Trial name
- NCT03995472
- Testing
- SHR-1501, SHR-1316
- Where
- 5 sites in Australia, China
- Volunteers
- 14 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-7367 in subjects with advanced solid tumors.
- Trial name
- NCT05740202
- Testing
- SHR-7367
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen
Hematologic Tumors
Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
- Trial name
- NCT00675350
- Testing
- Omacetaxine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- ChemGenex Pharmaceuticals
Advanced Solid Tumours, Cervical Cancer
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
This study is an open, multi-dose, dose escalation and cohort expansion, phase Ⅰ study to investigate the safety, tolerability, efficiency, pharmacokinetics, immunogenicity of SG001 in subjects with advanced tumours.
- Conditions
- Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma
- Trial name
- NCT03852823
- Testing
- SG001
- Where
- China
- Volunteers
- 192 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Colorectal Cancer, Advanced Solid Tumors
MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)
Study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors.
- Trial name
- NCT00099346
- Testing
- MK0457, VX-680 (Aurora Kinase Inhibitor)
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination…
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Trial name
- KAT6 (NCT04606446)
- Testing
- PF-07248144, Fulvestrant, Letrozole
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 320 people
- Sponsor
- Pfizer
Advanced Malignant Solid Tumors
Study Evaluating Safety And Tolerability, Solid Tumor
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
- Trial name
- NCT00768469
- Testing
- Neratinib, Paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Puma Biotechnology, Inc.
Neoplasms, Non-small-cell Lung Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or…
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT06285097
- Testing
- PF-07820435, Sasanlimab
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 9 people
- Sponsor
- Pfizer